December 21, 2023 05:30 AM ESTUpdated 06:57 AM
Peer Review

Deck the halls with res­ig­na­tions: Lian­Bio CEO, CFO out; CRISPR Ther­a­peu­tics CMO to leave in Jan­u­ary

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ On Dec. 16, Yizhe Wang turned in his res­ig­na­tion as CEO of Lian­Bio, while board mem­ber and Per­cep­tive chief in­vest­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times